KAPA stock sentiment todayKairos Pharma Ltd

A micro-cap biotech struggling with dilution and liquidity issues, currently in a high-risk 'prove-it' phase following a massive reverse split.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for KAPA. Not financial advice.

The narrative is a tug-of-war between aggressive clinical optimism (potential 'cures') and harsh market realities. While some outlets are upgrading the stock on trial potential, the actual price action is dominated by news of a 1-for-7 reverse stock split and unusual selling volume.

• ·1-for-7 Reverse Stock Split dilution fears
• ·Interim Phase 2 trial data for KPT-7127
• ·Recent NYSE American listing volatility
• ·CEO-led hype regarding oncology breakthroughs

As a pre-revenue clinical-stage biotech, KAPA is burning cash with a limited runway. The reverse split indicates a desperate need to maintain listing requirements and potentially attract institutional investors, though fundamental valuation remains speculative.

• ·Market Cap: Micro-cap (<$50M est.)
• ·Revenue: $0 (Pre-commercial)
• ·Cash Runway: High concern / frequent financing rounds
• ·Share Structure: Significant consolidation via reverse split

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Mixed conviction — no decisive signal from insiders or the holder base.

• ·No open-market insider trades in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·High probability of further equity dilution to fund trials
• ·Clinical trial failure risk (common in early-stage oncology)
• ·Extremely low liquidity leading to high volatility and 'slippage'
• ·Regulatory hurdles with the FDA for lead candidates

How direct competitors stack up against KAPA right now.

• HOT
  GLUEMonte Rosa Therapeutics

  HOTTER — recently secured a massive $50M upfront deal with Roche, providing significantly better cash runway and validation than KAPA.

  See full analysis →
• NEUTRAL
  NXTCNextCure, Inc.

  BETTER — similar immunotherapy focus but maintains a much stronger cash-to-market-cap ratio and more advanced clinical pipeline.

  See full analysis →
• COLD
  BJDXBluejay Diagnostics

  SIMILAR — also facing delisting threats and high volatility, serving as a cautionary tale for micro-cap healthcare plays.

  See full analysis →

Consensus average of 2 analysts · median 84.00

Source: StockAnalysis.com · updated 2026-07-27

• Simply Wall St
  Kairos Pharma (NYSEAM:KAPA) - Stock Analysis
• Yahoo Finance
  All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy
• Benzinga
  Why Is Kairos Pharma Stock Falling Today? - Kairos Pharma (AMEX:KAPA)
• ChartMill
  Unusual Volume Stocks Today: MI, BIYA, SMXT Gain; VCIG and KAPA Slide
• Zacks Investment Research
  Should I buy Kairos Pharma, Ltd. (KAPA)
• Yahoo Finance
  Kairos Pharma Announces 1-for-7 Reverse Stock Split